Leap Therapeutics Inc. logo

Leap Therapeutics Inc.

LPTX | NASDAQ
Chart Builder DCF Calculator
$0.77
-$0.02 (-3.10%)
At close: Apr 01, 2026, 09:30 AM ET

Market Data

Market Cap
$31.86M
Enterprise Value
$24.27M
Beta
0.09
Average Volume
N/A
Shares Outstanding (Diluted)
176.26M
Shares Change YoY
325.29%
Institutional Ownership
N/A
Exchange
N/A
ISIN
N/A

Price Performance

Price Change 1M
N/A
Price Change 3M
N/A
Price Change 6M
N/A
Price Change YTD
N/A
Price Change 1Y
N/A
Price Change 3Y
N/A
Price Change 5Y
N/A
1M CAGR (ann.)
141.1%
1Y CAGR (ann.)
-46.2%
5Y CAGR (ann.)
-39.7%
All-Time CAGR
-35.0%

Valuation

PE Ratio
1.22
Forward PE
2.65
PEG Ratio
-0.00
Forward PEG
-0.00
PS Ratio
152.42
Forward PS
0.50
PB Ratio
0.23
P/FCF Ratio
-0.50
P/Adj. FCF Ratio
-0.46
P/OCF Ratio
-2.08
EV/Sales
116.12
EV/EBIT
-1.85
EV/EBITDA
-1.37
EV/FCF
-0.38
Earnings Yield
81.8%
FCF Yield
-200.4%
Adj. FCF Yield
-219.4%

Financial Health

Net Cash
$7.59M
Total Debt
$38K
Cash & Short-Term Investments
$7.62M
Total Assets
$142.97M
Current Ratio
79.19
Quick Ratio
79.19
Debt / Equity Ratio
0.00
Debt / EBITDA
-0.00
Debt / FCF
-0.00
OCF / Debt
-1,733.16
Interest Coverage
8,887.50
Altman Z-Score
1.18
Piotroski F-Score
3

Margins & Profitability

Gross Profit Margin
-9631.6%
Operating Profit Margin
-8504.8%
EBITDA Margin
-8504.8%
Net Profit Margin
17655.5%
FCF Margin
-30551.2%
Adj. FCF Margin
-33447.4%
SBC / Revenue
2896.2%
SBC Impact (per share)
-9.5%

Returns

Return on Assets
25.8%
Return on Equity
23.8%
Return on Invested Capital
-12.6%
Return on Capital Employed
-12.6%
Return on Tangible Assets
25.8%

Historical Growth (CAGR)

Revenue CAGR 3Y
-60.7%
Revenue CAGR 5Y
-51.4%
Revenue CAGR 10Y
-1.3%
EPS CAGR 3Y
133.7%
EPS CAGR 5Y
55.5%
EPS CAGR 10Y
32.4%
FCF CAGR 3Y
-11.9%
FCF CAGR 5Y
-10.3%
FCF CAGR 10Y
-10.6%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
4
EPS Growth Next 3Y
-45.3%
Revenue Growth Next 3Y
473.5%
Earnings Date
May 17, 2026
EPS Estimate (next Q)
-$0.04
EPS Growth Est (next Q)
-89.0%
Revenue Est (next Q)
N/A
Revenue Growth Est (next Q)
N/A

Fair Value Estimates

Graham Number
$3.35
Graham Upside
335.1%
Lynch Fair Value
$15.75
Lynch Upside
1945.5%
Price Target
$5.50
Price Target Upside
614.3%

Cash Flow

Operating Cash Flow
$-65.86M
Free Cash Flow
$-63.85M
Adj. Free Cash Flow
$-69.91M
FCF Per Share
-$0.36
OCF Per Share
-$0.37
OCF/S Ratio
-31512.0%

Income Statement

Revenue
$209K
Gross Profit
$-20.13M
Operating Income
$-17.78M
EBITDA
$-17.78M
Net Income
$36.9M
EPS (Diluted)
$0.63
Revenue / Employee
N/A
Profit / Employee
N/A
Employees
N/A

© 2026 bestshares.com. All rights reserved.